1. Home
  2. WETH vs SNGX Comparison

WETH vs SNGX Comparison

Compare WETH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WETH

Wetouch Technology Inc.

HOLD

Current Price

$1.77

Market Cap

16.6M

Sector

N/A

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.10

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WETH
SNGX
Founded
1992
1987
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6M
14.4M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
WETH
SNGX
Price
$1.77
$1.10
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
44.4K
181.8K
Earning Date
11-12-2025
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
81.55
N/A
EPS
0.62
N/A
Revenue
$43,519,385.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.74
N/A
Revenue Growth
6.08
N/A
52 Week Low
$0.76
$1.02
52 Week High
$3.68
$6.23

Technical Indicators

Market Signals
Indicator
WETH
SNGX
Relative Strength Index (RSI) 52.39 35.32
Support Level $1.44 $1.04
Resistance Level $1.79 $1.16
Average True Range (ATR) 0.14 0.08
MACD 0.01 -0.01
Stochastic Oscillator 62.92 17.95

Price Performance

Historical Comparison
WETH
SNGX

About WETH Wetouch Technology Inc.

Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: